About
Dr. Bernard Bright Davies-Teye is a Post-Doctoral Fellow, Solid Tumor (GU) Real World Value & Evidence (RWVE) at Johnson & Johnson Innovative Medicine through the Rutgers HOPE (Center for Health Outcomes, Policy, and Economics) fellowship program with Johnson & Johnson.
A physician by clinical training, Bernard earned his MPH and later completed his PhD in Pharmaceutical Health Services Research at the University of Maryland School of Pharmacy. His dissertation examined real-world multilevel factors influencing treatment utilization, outcomes, and costs in localized prostate cancer using SEER-Medicare data linked with social determinants of health measures. The research generated actionable insights into treatment disparities, unmet treatment needs and drivers of care, helping to inform clinical decision-making, payer evaluations, and policy aimed at advancing treatment optimization equity in localized prostate cancer care.
Prior to this, Bernard completed a three-year pre-doctoral fellowship focused on outcomes research in cardiovascular diseases and solid tumors, particularly non–muscle-invasive and muscle-invasive bladder cancer (NMIBC and MIBC). During this fellowship, Bernard served as first author on research published in respected journals such as Clinical Genitourinary Cancer and Cancer Medicine. These studies, developed in close collaboration with his coauthors, provided actionable evidence on treatment trends, survival, and unmet clinical needs in bladder cancer, potentially informing both clinical practice and ongoing drug development.
At Rutgers HOPE | J&J, Bernard will be focused on developing and executing high-impact real-world evidence and strategies to support value demonstration, market access, and patient-centered innovation in GU oncology and Cardiometabolic diseases.